Step Forward
Personalize treatment decisions for RA patients
PrismRA® is a first-of-its kind molecular signature test that gives providers objective insights to drive RA treatment decisions.
The blood test analyzes each patient’s unique molecular signature, predicting if a patient is well suited for TNF inhibitor (TNFi) therapies such as adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab.1
Now, providers can help improve their patients’ outcomes by identifying those unlikely to respond adequately to TNFi therapies before you prescribe or modify treatment.
Results you can act on
PrismRA predicts a patient’s likelihood of non-response to TNFi therapies.
NO SIGNAL
Molecular signal of non-response not detected
HIGH
likelihood of non-response
VERY HIGH
likelihood of non-response
PrismRA can be easily incorporated into your practice
